


Hitotsubashi University Institute of Innovation Research



Institute of Innovation Research Hitotsubashi University

Tokyo, Japan http://www.iir.hit−u.ac.jp

A Cost Benefit Analysis of AminoIndex[™] Cancer Screening in Japan

Masaoki Tamura¹, Akira Imaizumi², Takahiko Muramatsu^{2,3}, Nobuhisa Shimba²,

- 1 : Graduate School of Pharmaceutical Sciences, Kyoto University
- 2 : AminoIndex Dept., AJINOMOTO, CO., INC.
- 3 : Institute for Innovation, AJINOMOTO, CO., INC.

Abstract:

This article presents a cost benefit analysis of AminoIndex[™] Cancer Screening (AICS) in Japan. AICS is a new cancer diagnosis method based on profiles of amino acids. The cost benefit analysis is performed on each type of cancer, each sex, and each age class. The results indicate that AICS is cost-beneficial mainly for 50-75 years old for screening of several types of cancer including stomach, lung, and colorectal cancer. AICS is also cost-beneficial for younger female for screening of uterine-ovarian cancer.

1. Introduction

Cancer is the most popular cause of death in Japan. In 2010, 29.5% of the Japanese people die from cancer. The reasons for this include lengthened life expectancies and changes in dietary habits. The prevention, early detection and treatment for cancer are becoming more and more important. Especially for early detection of cancer, cancer screening is known as one of the most effective ways. The government currently recommends cancer screening by distributing coupons and providing consultation services. Though there are evidences that show the current cancer screening is effective for early detection and decreasing death from cancer, there is still more needs for them. In addition, the current cancer screening is limited to several type of cancer.

Recently new technological progress leads to a new method of cancer screening: AminoIndexTM Cancer Screening (AICS). AICS is a new cancer diagnosis method based on profiles of amino acids. As shown in ..., AICS is effective for early detection of cancer from a medical and scientific point of view. However, the economic effectiveness of AICS is still an open question. The economic effectiveness refers to the economic benefit of patients compared to the economic cost of patients. The economic effectiveness is important because the patients choose and demand a medical test by taking into account their benefit and cost. Therefore, whether they demand a medical test, or equivalently whether it contributes to the welfare of the people, depends on the economic effectiveness. This article gives a cost-benefit analysis of AICS and measures the economic effectiveness of AICS. Specifically, we can answer to the following questions: when should we take AICS? Who should take AICS? For what types of cancer is AICS effective? We also evaluate the current cancer screening.

This article is organized as follows. In section 2, we overview the technological aspect of AICS. Section 3 gives the cost-benefit analysis of AICS. Section 4 conducts sensitivity analysis. In section 5, we present the data source that we employ in our analysis. Section 6 concludes this article.

2. Technical Characteristics of AminoIndexTM Cancer Screening (AICS)

Various screening methods have been established for the cancers. For gastric cancer, both X-ray examination and endscope is used for screening. For lung cancer, both X-ray and sputum cytology is used. In other case, fecal occult blood examination for colorectal cancer, prostate specific antigen (PSA) for prostate cancer, mammography and clinical breast examination for breast cancer, and cytology for cervix cancer, are used generally, respectively. However, the high specificity of these methods means that subjects must undergo each screening examination separately, which can be expensive and time consuming. These examinations can also impose a physical and/or mental burden upon subjects, which can lead to avoidance. By contrast, the method described in the present study involves a relatively simple plasma assay and imposes a lower physical burden on subjects.

Several rapid advances have been made in easy-to-use cancer diagnosis methods based on profiles of metabolites using biological samples such as peripheral blood and urine. Among several metabolites, amino acids are among the most suitable candidates as their physiological characteristics. Especially, plasma free amino acids (PFAAs), which abundantly circulate as a medium linking all organ systems, would be the most favorable target because their profiles have been known to be altered by specific diseases including cancer^{1,2)}.

Additionally, analytical technologies have recently been developed to analyze amino acids with high accuracy by means of high-performance liquid chromatography (HPLC)–electrospray ionization (ESI)–mass spectrometry (MS).

Many studies have also reported changes in PFAA profiles in various diseases including cancer. However, despite evidence of a relationship between PFAA profiles and diseases, few studies have explored the use of PFAA profiles for practical diagnosis. Although PFAA profiles differ significantly between patients, the discriminating ability of the difference of concentration of single plasma amino acid was not sufficient for clinical use. To overcome this problem, we established the concept of the "AminoIndex technology", to compress multidimensional information from PFAA profiles into single dimension and maximize the differences between patients and controls (Figure 1)³).

In general, multivariate discriminating function is inferred as described below;

- 1. Multivariate analysis with variable selection; usually, linear models such as linear regression analysis, logistic regression analysis, linear discrimination analysis, etc, are used according to the characteristics of the case and model. Variable selection is to be performed as stepwise variable selection, or model selection among all the possible combinations based on specific statistics such as Akaike Information Criterion (AIC), Area under Curve (AUC) of Receiver Operator Characteristics (ROC) curve, and so on.
- 2. Cross validation: then cross validation (CV) was performed to correct potential over-optimization for obtained model. For example, leave one out cross validation (LOOCV) is the most preferable method. In brief, one sample was omitted from the study data set, and the model was calculated for the remaining samples to estimate coefficients for each amino acid. The function values for the left-out sample were calculated based on the model. This process was repeated until every sample in the study data set had been left out once. Else, hold out method, or bootstrap method is also to be used.

Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, prostate, or gynecologic cancers, i.e. cervix, endometrial, and ovarian cancers, including early stage cancer patients. Patients were compared to five age- and gender-matched control groups. Index for each cancer was estimated by conducting with multivariate logistic regression analysis using plasma concentrations of amino acids as explanatory variables and presence (=1) or absence (=0) of cancer as objective variable, respectively³⁾.

After inferring of statistically most suitable models, the validities of the models were estimated using independent validation data $set^{4,5}$.




Figure 1. Concept of the "AminoIndex Technology"3).

By means of validation, using independent validation data set, clinical characteristics of AICS test have been estimated. In general, performance of clinical assay is to be estimated by sensitivity, specificity, and positive predictive value (PPV). Conceptually, the result of clinical assay is categorized into four groups as shown, true positive, true negative, false positive, and false negative. Sensitivity is determined as the ratio of true positive to summation of true positive and false negative (A/A+B), specificity is determined as the ratio of true negative and false positive (D/C+D), respectively. PPV is determined as the ratio of true positive to summation of true positive and false positive (A/A+C). Both sensitivity and specificity is not to be influenced the frequency of the patient of the subjects (prevalence, (A+B)/(A+B+C+D)) whereas PPV is to be influenced strongly by prevalence.

	With disease	Without disease
Test positive	True positive (A)	False positive (C)
Test negative	False negative (B)	True negative (D)

Sensitivities and at specificities are 80% and 95% for each cancer are as summarized below^{4,5};

	Sensitivity at 80% specificity	Sensitivity at 95% specicifity
Gastric cancer	75%	51%
Lung cancer	73%	45%
Colorectal cancer	60%	41%
Prostate cancer	64%	32%
Breast cancer	47%	20%
Gynecologic cancer	80%	58%

For PPV estimation, prevalence is substituted the incidence rate data from "A Study of 21 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project" was used because there are no available prevalence data in Japan⁶.

Besides those parameters, AICS test has noteworthy characteristics from the view point of early detection. Almost same sensitivity is observed regardless the cancer stage in AICS test while decrease of sensitivities for early stage cancer is broadly observed in existing method used in population-based screening. Early detection of cancer is one of the effective provision to decrease of the death from cancer for several cancer.

In summary, AICS test is simple, high-throughput and versatile method for early detection of several kinds of cancer.

3. Cost-Benefit Analysis

3-1. Overview of Our Method

Our analysis is based on the incremental cost-benefit analysis. The incremental cost-benefit analysis compares the increased cost and increased benefit when a new treatment would be taken in addition to a basic treatment, and evaluates the economic efficiency of the new treatment. In our case, we compares the increased cost and increased benefit when patients undergo AICS in addition to the normal cancer screening, and indicates whether AICS is efficient for patients to take in the economic sense.

For this purpose, we consider two scenarios:

- (1) Patients undergo cancer screening.
- (2) Patients undergo both cancer screening and AICS.

We estimate the cost and benefit in each scenario. C1 denotes the cost of case (1), and C2 denotes the cost of case (2). B1 denotes the benefit of case (1), and B2 denotes the benefit of case (2). Then, the incremental cost is defined as C1 – C2, and the incremental benefit is defined as B1 – B2. Then, we calculate the index of the economic efficiency of AICS when patients would take AICS in addition to the cancer screening.

Incremental Cost-benefit Ratio = Incremental Benefit of AICS / Incremental Cost of AICS = (B1 - B2) / (C1 - C2)

If the incremental cost-benefit ratio exceeds 1, we conclude that the case (2) is better than the case (1). In other words, AICS is desirable for patients to undergo. On the other hand, if the incremental cost-benefit ratio is lower than 1, we conclude that case (2) is worse than the case (1). In other words, AICS is not desirable for patients to undergo.

Note that our incremental cost-benefit analysis indicates whether AICS should be taken from patients' point of view, not from society's point of view. Our analysis is on the patients' decision for AICS, and hence only focuses on the patients' own payments and own benefit. However, we can alternatively consider other types of cost and benefit. For example, the national health insurance has to pay for the treatment of cancer, and the increased survival rate of patients give positive externality to the productivity of the whole economy. In our analysis, these social cost and benefit are not taken into account.

3-2. Action Trees

For the estimation of the cost and benefit in each scenario (C1, C2, B1, and B2), we need to clarify the actions that patients take in each scenario. We employ the action trees to illustrate what actions patients take and how each of C1, C2, B1, and B2 is measured.

The action tree for the patients with and without cancer in case (1) is shown in the figure 2. Patients are assumed to take these actions in case (1). We divide the patients into two types: "with cancer" and "without cancer".

First, consider the patients with cancer. The patients take the cancer screening. The cancer screening test shows positive or negative. If it is positive, they undergo a detailed examination. The examination can detect both early and advanced cancer. When the cancer is detected at the early stage, the patients take unserious treatment and survival rate is relatively high. Note that, on the other hand, the cancer screening can show false negative. If it is (false) negative, they do not undergo a detailed examination. No examination can not detect early cancer, and in a while patients are found to have advanced cancer. When the cancer is at the advanced stage, the patients take serious treatment and survival rate is relatively low.

Second, consider the patients without cancer. The patients take the cancer screening. The cancer screening test shows positive or negative. Note that there can be false positive in the cancer screening. If it is (false) positive, they undergo a detailed examination. If it is negative, they do not undergo a detailed examination. However, whichever they undergo examination or not, they are found to have no cancer, and receive no treatment.

Positive	Exam
Negative	No Exam




Figure 2. Action Tree in the Case (1)

The action tree for the patients with and without cancer in case (2) is shown in the figure 3. First, consider the patients with cancer. The patients take both the cancer screening and AICS. The cancer screening and AICS are positive or negative respectively. If at least one of them is positive, they undergo a detailed examination. The examination can detect both early and advanced cancer. When the cancer is detected at the early stage, the patients take unserious treatment and survival rate is relatively high. Note that, on the other hand, the cancer screening and AICS can show false negative. If both of them are (false) negative, they do not undergo a detailed examination. No examination can not detect early cancer, and in a while patients are found to have advanced cancer. When the cancer is at the advanced stage, the patients take serious treatment and survival rate is relatively low. It should be noted that the possibility of cancer detection in the case (2) is calculated as follows:

Possibility of Cancer Detection = Incidence Rate \times {1 - (1 - Sensitivity) \times (1 - AICS Sensitivity) }.

Especially for patients with early stage, the possibility of cancer detection in the case (2) is calculated as follows:

Possibility of Early Stage Cancer Detection = Incidence Rate \times {1 - (1 - Sensitivity×ratio of early stage cancer detected in existing screening) × (1 - AICS Sensitivity×ratio of early stage cancer detected in AICS)},

where ratio of early stage cancer detected in existing screening is determined by


<u>http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/cancer_s</u> <u>urvival(1993-2005).xls</u> and ratio of early stage cancer detected in existing screening is assumed as 80%.

Second, consider the patients without cancer. The patients take both the cancer screening and AICS. The cancer screening and AICS are positive or negative respectively. Note that there can be false positive in the cancer screening and AICS. If at least one of them is (false) positive, they undergo a detailed examination. If both of them are negative, they do not undergo a detailed examination. However, whichever they undergo examination or not, they are found to have no cancer, and receive no treatment. It should be noted that the possibility of false positive in the case (2) is calculated as follows:

Possibility of False Positive =

(1 – Incidence Rate) $\,\times\,$ (1-Specificity $\,\times\,$ AICS Specificity)

CST 📉 AICS	AICS Positive	AICS Negative
Positive	Exam	Exam
Negative	Exam	No Exam






Figure 3. Action Tree in the Case (2)

In the following, we summarize the cost and benefit that derives from the action trees above.

3-3. Cost

The cost of case (1) consists of two parts: the fee of the cancer screening test and the fee of the examination. First, all of the patients pay for cancer screening. Second, if they are found positive, they undergo the examination, and additionally pay for it. If they are found negative, they do not pay any more. Note that there can be a case of false positive in which patients without cancer are found positive, and pay for the examination. In this case, the payment is just a cost that yields no benefit.

The cost of case (2) consists of three parts: the fee of cancer screening test, the fee of AICS, and the fee of the examination. First of all, the patients undergo the cancer screening and AICS. They pay for both tests. Second, if one of the tests indicates positive, they undergo the examination, and additionally pay for it. Otherwise, they do not undergo the examination, and do not pay any more. In other words, the patients do not pay any more only if both tests are negative. Note that there can be a case of false positive in which patients without disease are found positive, and pay for the examination.

3-4. Benefit

As seen in section 3-2, we assume that the patients with cancer who do not undergo the examination are found to have advanced cancer. On the other hand, the patients with cancer who undergo the examination are found to have early or advanced cancer. To sum up, the cancer screening and AICS help them to detect early cancer through the examination.

The cancer screening and AICS leads to early detection of cancer, which benefit the patients in three ways: first, early detection of cancer reduces the direct treatment cost for cancer. This is because the treatment cost for early cancer is smaller than the treatment cost for advanced cancer. This direct treatment cost includes cost of hospitalization, cost of treatment including surgery, radiotherapy, and chemotherapy, and other medical cost such as dietary and recuperation. For example, the treatment cost of early lung cancer is 673855 JPY though that of advanced lung cancer is 2695421 JPY.

Second, early detection reduces indirect productivity loss from hospitalization and recess. In cancer treatment, patients need to be in hospital. This hospitalization period is shorter for early cancer than for advanced cancer. In addition, patients have to heal oneself at home after leaving hospital to return to business. Therefore, it is regarded as benefit for the patients. However, in a cost-benefit analysis, we should evaluate the benefit not in terms of time length, but in terms of money. As an approximation, by calculating average income multiplied by average work suspension period, we estimate income loss (productivity loss) that would be earned if patients would not be under recuperation. Early detection reduces hospitalization and work suspension period, and hence income loss, that would be caused by lost-worktime.

Third, early detection of cancer increases the survival rate of the patients. The survival rate of early cancer is higher than that of advanced cancer. For example, the survival rate of early (i.e. localized) lung cancer is 77.2%, though that of advanced lung cancer is 3.7 - 23.1% depending on metastasis. Then, how can we evaluate the increased survival rate of the patients from economics point of view? One approximation is the increase of life time income. If the patients could live shorter, they would lose more future income. In short, early detection of cancer reduces future income loss. We regard this as the third source of the benefit from the cancer screening and AICS.

In addition, the benefit is calculated according to

$$B_i = \sum_{t=1}^T \frac{Y_t}{(1+\rho)^t}$$

where Y_t denotes the income that would be lost when patients do not undergo AICS, ρ denotes the discount rate. In this article, we use apply ρ =0.04. To calculate this value, we need the data of average income for each sex and age class.

3-5. Results

We calculate the incremental cost-benefit ratio ((B1 - B2) / (C1 - C2)) for each kind of cancer, each age class, and each sex. It should be noted that if the incremental cost-benefit ratio exceeds 1, we conclude that AICS is desirable for patients to take. On the other hand, if the incremental cost-benefit ratio is lower than 1, we conclude that AICS is not efficient for patients to take.

The results are shown in the table 3 and figure 4. For 6 cancer, (B1 - B2) / (C1 - C2) > 1 for age over 50. For stomach cancer, (B1 - B2) / (C1 - C2) > 1 mainly for male over 50. For lung cancer, (B1 - B2) / (C1 - C2) > 1 mainly for male over 50. For colorectal cancer, (B1 - B2) / (C1 - C2) > 1 mainly for age over 55. For prostate cancer, (B1 - B2) / (C1 - C2) < 1 for all male age class. For breast cancer, (B1 - B2) / (C1 - C2) > 1 for all female age class. For uterine-ovarian Cancer, (B1 - B2) / (C1 - C2) > 1 for female 45-60.

These results indicate that AICS is desirable mainly for 50-75 years old for screening of several types of cancer including stomach, lung, and colorectal cancer. AICS is also desirable for younger female for screening of uterine-ovarian cancer.

All cancer

All cancer																	
Sex			Female														Female
Age		40		45	45	50	50	55	55	60	60	65	65	70	70	75	75
Benefit(B2-B1)	Total	5304	7380	10731	11211	18673	14481	28879	15837	36721	15750	43858	16079	47457	17195	37396	16423
	Therapy	136	584	298 10363	927	597	1189	1132	1397	1939	1549	3793	2104	5786	2600	8262	3267
	Opportunity Productivity	5136 32	6635 161	70	10034 249	17918 158	13013 279	27433 314	14151 290	34348 435	13956 245	39475 590	13748 227	40831 840	14337 258	28130 1004	12886 270
Cost(C2-C1)	Total	22204	22664	22204	22666	22205	22668	22206	22669	22208	22669	22211	22669	22215	22670	22219	22670
0000(02 01)	Screening	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900	18900
	Examination	3304	3764	3304	3766	3305	3768	3306	3769	3308	3769	3311	3769	3315	3770	3319	3770
(B2-B1)-(C2-C1)		-16900	-15284	-11473	-11455	-3532	-8188	6673	-6832	14513	-6919	21646	-6590	25242	-5475	15177	-6247
(B2-B1)/(C2-C1)		0.24	0.33	0.48	0.49	0.84	0.64	1.30	0.70	1.65	0.69	1.97	0.71	2.14	0.76	1.68	0.72
Stomach o	cancer																
Sex																	Female
Age	Tabal	40		45	45	50	50	55	55	60	60	65	65	70	70	75	75
Benefit(B2-B1)	Total	2370 52	859 37	4456	1384	7403 200	1879 97	11515 377	2379	13793	2687	15650 1182	3528 356	16583 1764	4358 529	11637 2324	4444
	Therapy	2306	818	106 4325	65 1313	7154	1772	11050	138 2228	595 13094	180 2493	14343	3152	14642	3798	9099	741
	Opportunity Productivity	2306	4	4325	7	49	1//2	89	14	13094	2495	14343	20	14642	3798	214	3664 39
Cost(C2-C1)	Total	5405	4460	5405	4460	5406	4460	5406	4460	5406	4461	5407	4461	5407	4461	5408	4461
031(02 01)	Screening	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780
	Examination	680	680	680	680	681	680	681	680	681	681	682	681	682	681	683	681
(B2-B1)-(C2-C1)	Examination	-3035	-3601	-949	-3076	1997	-2582	6109	-2081	8387	-1773	10243	-932	11176	-103	6229	-17
(B2-B1)/(C2-C1)		0.44	0.19	0.82	0.31	1.37	0.42	2.13	0.53	2.55	0.60	2.89	0.79	3.07	0.98	2.15	1.00
	201																
Lung cano	Jer	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Sex Age		Male 40	Female 40	Male 45	Female 45	Male 50	Female 50	Male 55	Female 1 55	viaie 60	remaie 60	Male 65	Female 65	Male 70	Female 70	Male 75	Female 75
Benefit(B2-B1)	Total	1560	536	3788	1099	6662	1903	9917	2734	13180	3533	16023	4108	18109	4815	16128	4896
	Therapy	43	29	112	63	224	121	403	195	705	290	1229	419	1964	594	3228	810
	Opportunity	1517	507	3675	1036	6438	1782	9512	2538	12473	3242	14791	3688	16142	4221	12895	4085
	Productivity	0	0	0	0	1	0	2	0	2	0	3	0	4	1	6	1
Cost(C2-C1)	Total	5689	4744	5689	4744	5690	4744	5690	4745	5691	4745	5692	4745	5694	4746	5697	4746
	Screening	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780
	Examination	964	964	964	964	965	964	965	965	966	965	967	965	969	966	972	966
(B2-B1)-(C2-C1)		-4129	-4208	-1901	-3645	972	-2841	4226	-2011	7489	-1212	10331	-638	12415	70	10432	150
(B2-B1)/(C2-C1)		0.27	0.11	0.67	0.23	1.17	0.40	1.74	0.58	2.32	0.74	2.81	0.87	3.18	1.01	2.83	1.03
Colorectal	l cancer																
Sex			Female														Female
Age		40		45	45	50	50	55	55	60	60	65	65	70	70	75	75
Benefit(B2-B1)	Total	1356	556	2405	828	4158	1564	6210	2083	7087	2512	8010	2947	7709	3316	5640	3494
	Therapy	40	32 517	76	51	148 3929	105	266	157	400 6530	219 2253	783	383 2515	1084	532	1459	779 2629
	Opportunity Productivity	1297 20	8	2289 41	765 13	82	1434 25	5802 141	1890 35	157	40	7041 186	49	6390 235	2717 66	3902 279	2029
Cost(C2-C1)	Total	5685	4740	5685	4740	5686	4740	5686	4741	5686	4741	5687	4741	5688	4741	5688	4742
CUSI(C2-C1)	Screening	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780	4725	3780
	Examination	960	960	960	960	961	960	961	961	961	961	962	961	963	961	963	962
(B2-B1)-(C2-C1)	Examination	-4329	-4184	-3280	-3912	-1527	-3176	501	-2658	1400	-2228	2323	-1794	2021	-1425	-48	-1248
(B2-B1)/(C2-C1)		0.24	0.12	0.42	0.17	0.73	0.33	1.09	0.44	1.25	0.53	1.41	0.62	1.36	0.70	0.99	0.74
Prostate o	ancer																
Age		40	40	45	45	50	50	55	55	60	60	65	65	70	70	75	75
Benefit(B2-B1)	Total	17		82	.5	450	50	1237	55	2662	00	4175	0.5	5056	70	3990	, 5
	Therapy	1/		4		430		85		239		599		974		1251	
	Opportunity	16		73		398		1069				3300		3657			
	Productivity	10								2251						2234	
Cost(C2-C1)	Total			4		26		82				276					
	Screening	5424		4 5424		26 5424				172 5425		276 5425		425 5426		2234 505 5427	
		5424 4725						82		172				425		505	
	Examination			5424		5424		82 5424		172 5425		5425		425 5426		505 5427	
(B2-B1)-(C2-C1)	Examination	4725	0	5424 4725	0	5424 4725	0	82 5424 4725	0	172 5425 4725	0	5425 4725	0	425 5426 4725	0	505 5427 4725	0
(B2-B1)-(C2-C1) (B2-B1)/(C2-C1)	Examination	4725 699	0	5424 4725 699	0	5424 4725 699	0	82 5424 4725 699	0	172 5425 4725 700	0	5425 4725 700	0	425 5426 4725 701	0	505 5427 4725 702	0
(B2-B1)/(C2-C1)		4725 699 -5407	0	5424 4725 699 -5342	0	5424 4725 699 -4974	0	82 5424 4725 699 -4187	0	172 5425 4725 700 -2763	0	5425 4725 700 -1250	0	425 5426 4725 701 -370	0	505 5427 4725 702 -1436	0
(B2-B1)/(C2-C1) Breast ca		4725 699 -5407	0 Female	5424 4725 699 -5342 0.02		5424 4725 699 -4974 0.08	0 Female	82 5424 4725 699 -4187 0.23		172 5425 4725 700 -2763	0 Female	5425 4725 700 -1250 0.77		425 5426 4725 701 -370	0 Female	505 5427 4725 702 -1436 0.74	0 Female
(B2-B1)/(C2-C1) Breast can Sex		4725 699 -5407 0.00	Female	5424 4725 699 -5342 0.02		5424 4725 699 -4974 0.08 Male		82 5424 4725 699 -4187 0.23 Male	Female 1	172 5425 4725 700 -2763 0.49		5425 4725 700 -1250 0.77		425 5426 4725 701 -370 0.93		505 5427 4725 702 -1436 0.74	
(B2-B1)/(C2-C1) Breast can Sex Age		4725 699 -5407 0.00 Male	Female	5424 4725 699 -5342 0.02 Male	Female	5424 4725 699 -4974 0.08 Male	Female	82 5424 4725 699 -4187 0.23 Male	Female 1	172 5425 4725 700 -2763 0.49 Male	Female	5425 4725 700 -1250 0.77 Male	Female	425 5426 4725 701 -370 0.93 Male	Female	505 5427 4725 702 -1436 0.74 Male	Female
(B2-B1)/(C2-C1) Breast can Sex Age	ncer	4725 699 -5407 0.00 Male	Female 40	5424 4725 699 -5342 0.02 Male	Female 45	5424 4725 699 -4974 0.08 Male	Female 50	82 5424 4725 699 -4187 0.23 Male	Female 1 55	172 5425 4725 700 -2763 0.49 Male	Female 60	5425 4725 700 -1250 0.77 Male	Female 65	425 5426 4725 701 -370 0.93 Male	Female 70	505 5427 4725 702 -1436 0.74 Male	Female 75
(B2-B1)/(C2-C1) Breast can Sex Age	ncer	4725 699 -5407 0.00 Male	Female 40 1665	5424 4725 699 -5342 0.02 Male	Female 45 2378	5424 4725 699 -4974 0.08 Male	Female 50 1989	82 5424 4725 699 -4187 0.23 Male	Female 1 55 1804	172 5425 4725 700 -2763 0.49 Male	Female 60 1624	5425 4725 700 -1250 0.77 Male	Female 65 1423	425 5426 4725 701 -370 0.93 Male	Female 70 1253	505 5427 4725 702 -1436 0.74 Male	Female 75 946
(B2-B1)/(C2-C1) Breast can Sex Age	ncer ^{Total} Therapy	4725 699 -5407 0.00 Male	Female 40 1665 254	5424 4725 699 -5342 0.02 Male	Female 45 2378 384	5424 4725 699 -4974 0.08 Male	Female 50 1989 348	82 5424 4725 699 -4187 0.23 Male	Female 1 55 1804 348	172 5425 4725 700 -2763 0.49 Male	Female 60 1624 355	5425 4725 700 -1250 0.77 Male	Female 65 1423 403	425 5426 4725 701 -370 0.93 Male	Female 70 1253 395	505 5427 4725 702 -1436 0.74 Male	Female 75 946 375
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1)	Total Therapy Opportunity	4725 699 -5407 0.00 Male	Female 40 1665 254 1317	5424 4725 699 -5342 0.02 Male	Female 45 2378 384 1850	5424 4725 699 -4974 0.08 Male	Female 50 1989 348 1515	82 5424 4725 699 -4187 0.23 Male	Female 1 55 1804 348 1337	172 5425 4725 700 -2763 0.49 Male	Female 60 1624 355 1170	5425 4725 700 -1250 0.77 Male	Female 65 1423 403 933	425 5426 4725 701 -370 0.93 Male	Female 70 1253 395 769	505 5427 4725 702 -1436 0.74 Male	Female 75 946 375 495
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1)	Total Therapy Opportunity Productivity Total Screening	4725 699 -5407 0.00 Male	Female 40 1665 254 1317 95 4475 3780	5424 4725 699 -5342 0.02 Male	Female 45 2378 384 1850 144 4476 3780	5424 4725 699 -4974 0.08 Male	Female 50 1989 348 1515 126 4475 3780	82 5424 4725 699 -4187 0.23 Male	Female 1 55 1804 348 1337 119 4475 3780	172 5425 4725 700 -2763 0.49 Male	Female 60 1624 355 1170 100 4475 3780	5425 4725 700 -1250 0.77 Male	Female 65 1423 403 933 87 4475 3780	425 5426 4725 701 -370 0.93 Male	Female 70 1253 395 769 89 4475 3780	505 5427 4725 702 -1436 0.74 Male	Female 75 946 375 495 77 4475 3780
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1)	Total Therapy Opportunity Productivity Total	4725 699 -5407 0.00 Male	Female 40 1665 254 1317 95 4475	5424 4725 699 -5342 0.02 Male	Female 45 2378 384 1850 144 4476	5424 4725 699 -4974 0.08 Male	Female 50 1989 348 1515 126 4475	82 5424 4725 699 -4187 0.23 Male	Female 55 1804 348 1337 119 4475	172 5425 4725 700 -2763 0.49 Male	Female 60 1624 355 1170 100 4475	5425 4725 700 -1250 0.77 Male	Female 65 1423 403 933 87 4475	425 5426 4725 701 -370 0.93 Male	Female 70 1253 395 769 89 4475	505 5427 4725 702 -1436 0.74 Male	Female 75 946 375 495 77 4475
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1)	Total Therapy Opportunity Productivity Total Screening	4725 699 -5407 0.00 Male	Female 40 1665 254 1317 95 4475 3780 695 -2810	5424 4725 699 -5342 0.02 Male	Female 45 2378 384 1850 144 4476 3780 696 -2098	5424 4725 699 -4974 0.08 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486	82 5424 4725 699 -4187 0.23 Male	Female 1 55 1804 348 1337 119 4475 3780 695 -2671	172 5425 4725 700 -2763 0.49 Male	Female 60 1624 355 1170 100 4475 3780 695 -2851	5425 4725 700 -1250 0.77 Male	Female 65 1423 933 933 87 4475 3780 695 -3052	425 5426 4725 701 -370 0.93 Male	Female 70 1253 395 769 89 4475 3780 695 -3222	505 5427 4725 702 -1436 0.74 Male	Female 75 946 375 495 77 4475 3780 695 -3529
(B2-B1)/(C2-C1) Breast ca: Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1)	ncer Total Therapy Opportunity Productivity Total Screening Examination	4725 699 -5407 0.00 Male 40	Female 40 1665 254 1317 95 4475 3780 695	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696	5424 4725 699 -4974 0.08 Male 50	Female 50 1989 348 1515 126 4475 3780 695	82 5424 4725 699 -4187 0.23 Male 55	Female 55 1804 348 1337 119 4475 3780 695	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 100 4475 3780 695	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695	425 5426 4725 701 -370 0.93 Male 70	Female 70 1253 395 769 89 4475 3780 695	505 5427 4725 702 -1436 0.74 Male 75	Female 75 946 375 495 77 4475 3780 695
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o	ncer Total Therapy Opportunity Productivity Total Screening Examination	4725 699 -5407 0.00 Male 40 0	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 1144 4476 3780 696 -2098 0.53	5424 4725 699 -4974 0.08 Male 50	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 100 4475 3780 695 -2851 0.36	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32	425 5426 4725 701 -370 0.93 Male 70	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28	505 5427 4725 702 -1436 0.74 Male 75	Female 75 946 375 495 77 4475 3780 695 -3529 0.21
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex	ncer Total Therapy Opportunity Productivity Total Screening Examination	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37 Female	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 Female	5424 4725 699 -4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0,44 Female	82 5424 4725 699 -4187 0.23 Male 55	Female 1 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 100 4475 3780 695 -2851 0.36 Female	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 Female	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 946 375 495 77 4475 3780 695 -3529 0.21 Female
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age	ncer Total Therapy Opportunity Productivity Total Screening Examination	4725 699 -5407 0.00 Male 40 0	Female 40 1655 254 1317 95 4785 3780 695 -2810 0.37 Female 40	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 Female 45	5424 4725 699 -4974 0.08 Male 50	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 7-2671 0.40	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 100 4475 3780 695 -2851 0.36 Female 60	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 0.32 Female 65	425 5426 4725 701 -370 0.93 Male 70	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70	505 5427 4725 702 -1436 0.74 Male 75	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 75 Female 75
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age	ncer Total Therapy Opportunity Productivity Total Screening Examination Varian ca	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 3780 695 -2810 0.37 Female 40 3763	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 0.53 Female 45 5521	5424 4725 699 4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50 7145	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 4475 3780 695 -2851 0.36 Female 60 5393	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 0.32 Female 65 4073	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70 3453	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 Female 75 2643
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age	Total Therapy Opportunity Productivity Total Screening Examination Varian ca Total Total	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37 Female 40 3763 232	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 1144 4476 3780 696 6 -2098 0.53 -2098 0.53 Female 45 5521 364	5424 4725 699 4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50 7145 518	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 4475 3780 695 -2851 0.36 Female 60 5393 506	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 0.32 Female 65 4073 543	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70 3453 550	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 Female 75 2643 563
(B2-B1)/(C2-C1) Breast ca: Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age	ncer Total Therapy Opportunity Productivity Total Examination Varian ca Total Therapy Opportunity	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 4475 3780 6490 -2810 0.37 Female 40 3763 232 23476	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 696 0.53 0.53 5521 364 45 5521 364 45 5071	5424 4725 699 4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50 7145 518 6509	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 4475 3780 64475 -2851 0.36 Female 60 5393 506 4797	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 -3052 0.32 -543 3460	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70 3453 550 2831	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 75 2643 5263 2013
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) (C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age Benefit(B2-B1)	ncer Total Therapy Opportunity Total Screening Examination Varian ca Total Therapy Opportunity Productivity	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37 Female 40 3763 232 34766 54	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 696 -2098 0.53 Female 45 5521 364 5071 86	5424 4725 699 -4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50 7145 518 6509 118	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158 212	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 100 4475 3780 695 -2851 0.36 503 506 4797 90	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 0.32 65 4073 543 3460 70	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70 3453 550 2831 71	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 4475 3780 695 -3529 0.21 Female 75 2643 563 2013 67
(B2-B1)/(C2-C1) Breast ca: Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age	Total Therapy Opportunity Productivity Total Screening Examination Varian ca Total Therapy Opportunity Productivity Total	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37 Female 40 3763 232 3476 54 4225	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 Female 45 5521 364 5071 86 6 4246	5424 4725 699 -4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 Female 50 7145 518 6509 1188 4248	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158 121 4248	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 3355 1170 4475 3780 695 -2851 0.36 505 5393 506 4797 90 90 4247	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 655 -3052 0.32 0.32 Female 65 4073 543 3460 700 4247	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 Female 70 3453 550 2831 71 4247	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 75 2643 563 2013 67 4246
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)-(C2-C1) Uterine-o Sex Age Benefit(B2-B1)	ncer Total Therapy Opportunity Productivity Total Examination Varian ca Examination Varian ca Total Therapy Opportunity Productivity Total Screening	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 3780 695 -2810 0.37 695 -2810 0.37 7 87 40 3763 232 23 476 54 4245 54 4245 3780	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 696 -2098 0.53 780 896 45 5521 364 45 5521 364 45 5071 86 4246 53780	5424 4725 699 -4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 695 -2486 695 -2486 507 7145 518 6509 118 4248 3780	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 1337 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158 121 4248 3780	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 4475 3780 695 -2851 60 5393 506 4797 90 4247 3780	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 0.32 543 3460 70 3460 70 4247 3780	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 10 -3222 -322 -3222 -322 -3222 -32 -3	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 Female 75 2643 563 2013 67 4246 3780
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) (Cost(C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-O Sex Age Benefit(B2-B1) Cost(C2-C1)	Total Therapy Opportunity Productivity Total Screening Examination Varian ca Total Therapy Opportunity Productivity Total	4725 699 -5407 0.00 Male 40 0 Male 40	Female 40 1665 254 1317 95 4475 3780 695 -2810 0.37 Female 40 3763 232 3476 54 4225	5424 4725 699 -5342 0.02 Male 45 Male	Female 45 2378 384 1850 144 4476 3780 696 -2098 0.53 Female 45 5521 364 5071 86 6 4246	5424 4725 699 -4974 0.08 Male 50	Female 50 1989 348 1515 126 4475 3780 695 -2486 0.44 54 518 6509 118 4248 3780 468	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158 121 4248 3780 428	172 5425 700 -2763 0.49 60 60 Male 60	Female 60 1624 355 1170 4475 3780 695 -2851 0.36 506 4797 90 4247 3780 467	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 655 -3052 0.32 0.32 Female 65 4073 543 3460 700 4247	425 5426 4725 701 -370 0.93 Male 70 Male 70	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 70 70 70 70 3453 550 2831 71 4247 3780 467	505 5427 4725 702 -1436 0.74 Male 75 Male 75	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 75 2643 563 2013 67 4246 3780 426
(B2-B1)/(C2-C1) Breast can Sex Age Benefit(B2-B1) (C2-C1) (B2-B1)-(C2-C1) (B2-B1)/(C2-C1) Uterine-o Sex Age Benefit(B2-B1)	ncer Total Therapy Opportunity Productivity Total Examination Varian ca Examination Varian ca Total Therapy Opportunity Productivity Total Screening	4725 699 -5407 0.00 Male 40 0 0 0	Female 40 1665 254 1317 95 3780 695 -2810 0.37 -2810 0.37 695 40 3763 232 3476 54 4245 3780 465	5424 4725 699 -5342 0.02 Male 45	Female 45 2378 384 1850 144 4476 3780 696 696 696 696 696 5552 364 55521 364 55521 364 5071 866 4246 3780 466	5424 4725 699 -4974 0.08 Male 0 Male	Female 50 1989 348 1515 126 4475 3780 695 -2486 695 -2486 695 -2486 509 7145 518 6509 118 4248 3780	82 5424 4725 699 -4187 0.23 Male 55	Female 1 55 1804 348 1337 119 4475 3780 695 -2671 0.40 Female 1 55 6838 559 6158 121 4248 3780 428	172 5425 4725 700 -2763 0.49 Male 60	Female 60 1624 355 1170 4475 3780 695 -2851 60 5393 506 4797 90 4247 3780	5425 4725 700 -1250 0.77 Male 65	Female 65 1423 403 933 87 4475 3780 695 -3052 0.32 Female 65 4073 543 3460 70 4247 3780 467	425 5426 4725 701 -370 0.93 Male 70 0 Male	Female 70 1253 395 769 89 4475 3780 695 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 0.28 -3222 10 -3222 -322 -3222 -322 -3222 -32 -3	505 5427 4725 702 -1436 0.74 Male 0 Male	Female 75 946 375 495 77 4475 3780 695 -3529 0.21 Female 75 2643 563 2013 67 4246 3780

Table 3. The Results of Cost-Benefit Analysis




Figure 4. The Results of Cost-Benefit Analysis

4. Sensitivity Analysis

We conduct sensitivity analysis in two ways: first, we vary discount rate from 0.01% to 10.00%. The results are presented in Figure 5. The higher the discount rate is, the lower the cost-effective ratio is. This is because the large part of benefit comes from increased survival rate of patients that is measured by estimating future income. The benefit of future income becomes lower if the discount rate becomes higher.

Second, we substitute individual income for family income. So far, we have employed individual income in the estimation. Women's benefit (value of life) is measured by women's income, and men's benefit (value of life) is measured by men's income. As a result, women's value of life is lower than men's value of life, because the women's income is lower than men's income. This is not reasonable in some cases. For example, some married women save work time in order to do housework and childcare. The value of life should reflect the value of housework and childcare, which is quite difficult in the estimation. One way to deal with this problem is that we regard one half of family income (that is the average income of men and women at the same age class) as the each individual's income. Then, the results of our analysis are summarized in Figure 6.




Figure 5. Sensitivity Analysis of Discount Rate




Figure 6. Sensitivity Analysis of Income Adjustment between Sexes

5. Statistics

In this section, we present the source of the data that we employ in the cost-benefit analysis.

The data of population in each generation is taken from National Census in 2010 of Statistics Bureau of Japan

(<u>http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001039448</u>). The data of average income in each generation is taken from

Minkan-Kyuyo-Jittai-Tokei-Chosa in 2012 of National Tax Agency Japan (https://www.nta.go.jp/kohyo/tokei/kokuzeicho/minkan2011/pdf/000.pdf). The data of average mortality is taken from Abridged Life Table in 2012 of Ministry of Health, Labour and Welfare

(http://www.mhlw.go.jp/toukei/saikin/hw/life/life11/dl/life11-11.xls). The cancer incidence rate in each generation is taken from Center for Cancer Control and Information Services, National Cancer Center, Japan (http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/cancer_i ncidence(1975-2010).xls). The survival rate of cancer patients is taken from Monitoring of Cancer Incidence in Japan - Survival 2003-2005 Report (http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/cancer_ survival(1993-2005).xls). The consultation rate of cancer screening is calculated from the reports of Ministry of Health, Labour and Welfare (http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/City_Ca ncer_Screening_Rate(2006-2010).xlsx_and

http://www.mhlw.go.jp/stf/houdou/2r9852000001igt0-att/2r9852000001iguh.

<u>pdf</u>). For gastric cancer, colorectal cancer, breast cancer, and cervical cancer, the sensitivity and specificity of cancer screening is taken from research papers of Daido Life Welfare Foundation

(http://www.daido-life-welfare.or.jp/research_papers/19/welfare_34.pdf). For lung cancer and prostate cancer, the sensitivity and specificity of cancer screening is taken from Cancer Screening and Management Division, Research Center for Cancer Prevention and Screening, National Cancer

(http://canscreen.ncc.go.jp/pdf/guideline/guide_lung070111.pdf and Center http://canscreen.ncc.go.jp/pdf/guideline/zenritsusenguide/zenritsusenguide.p <u>df</u>). The cost of cancer screening, Workup and Treatment for early and advanced cancer are research report estimated by Industrial Growth Platform Inc.(Tokyo, Japan) based on following web sources; http://www.mhlw.go.jp/bunya/kenkou/gan_kenshin.html, http://www.ganchiryohi.com/, and http://www.it-sui.com/cancer-treat-cost/, and hearing survey. Costs of hospitalization and therapy are taken from National Census in 2014 of Statistics Bureau of Japan (http://www.e-stat.go.jp/SG1/estat/GL08020103.do? xlsDownload &fileId=0 00006864950&releaseCount=1). Average hospitalization days is taken from the reports of Ministry of Health, Labour and Welfare (http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/dl/toukei.xls). The period of lost worktime is taken from reports of Bureau of Social Welfare and Public Health of Tokyo Metropolitan Government (http://www.fukushihoken.metro.tokyo.jp/iryo/iryo_hoken/gan_portal/soudan

/ryouritsu/handbook.files/kisochishiki.pdf).

6. Conclusions

This article investigates economic efficiency of AminoIndex[™] Cancer Screening (AICS) in Japan. The results indicate that, from patients' point of view, AICS is cost-beneficial mainly for 50-75 years old for screening of several types of cancer including stomach, lung, and colorectal cancer. AICS is also cost-beneficial for younger female for screening of uterine-ovarian cancer.

References:

1. Okamoto N, Miyagi Y, Chiba A, Akaike M, Shiozawa M, et al. (2009) Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci 1: 1-8.

2. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, et al. (2010) Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10: 690.

3. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, Saruki N, Bando E, Kimura H, Imamura F et al: Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011, 6(9):e24143.

4. Okamoto N: Cancer screening using "AminoIndex Technology". The Ningen Dock 2011, 26(3):454-466.

5. Miyagi E, Numazaki R, Nakanishi T, Kataoka F, Saruki N, et al. (2012) Diagnostic performance and clinical utility of novel gynecologic cancer screening method based on "AminoIndex Technology". The Ningen Dock 2012, 26(5): 749-755.

6. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H and The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2007: A Study of 21 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Japanese Journal of Clinical Oncology 2013, 43(3): 328-336.

7. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T; Research Group of Population-Based Cancer Registries of Japan. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Japanese Journal of Clinical Oncology 2011, (41): 40-51.